Citadel Advisors
AMRX icon

Citadel Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Citadel Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$522K Buy
+42,000
New +$564K ﹤0.01% 9199
2025
Q3 		– Sell
-11,900
Closed -$96.3K – 12679
2025
Q2 		$96.3K Sell
11,900
-40,400
-77% -$305K ﹤0.01% 11384
2025
Q1 		$438K Sell
52,300
-6,400
-11% -$53.4K ﹤0.01% 8767
2024
Q4 		$465K Buy
58,700
+56,500
+2,568% +$474K ﹤0.01% 8722
2024
Q3 		$18.3K Sell
2,200
-500
-19% -$3.91K ﹤0.01% 12849
2024
Q2 		$17.1K Sell
2,700
-13,700
-84% -$87K ﹤0.01% 12762
2024
Q1 		$99.4K Buy
16,400
+1,200
+8% +$6.77K ﹤0.01% 11365
2023
Q4 		$92.3K Buy
15,200
+13,400
+744% +$59.7K ﹤0.01% 11031
2023
Q3 		$7.6K Sell
1,800
-3,000
-63% -$11.2K ﹤0.01% 13250
2023
Q2 		$14.9K Sell
4,800
-800
-14% -$1.7K ﹤0.01% 12980
2023
Q1 		$7.78K Sell
5,600
-9,800
-64% -$19.5K ﹤0.01% 13699
2022
Q4 		$30.6K Buy
+15,400
New +$34.5K ﹤0.01% 12721
2022
Q2 		– Sell
-70,800
Closed -$295K – 12799
2022
Q1 		$295K Sell
70,800
-14,000
-17% -$62K ﹤0.01% 10633
2021
Q4 		$406K Buy
84,800
+61,700
+267% +$308K ﹤0.01% 10179
2021
Q3 		$123K Sell
23,100
-24,900
-52% -$125K ﹤0.01% 12615
2021
Q2 		$246K Buy
48,000
+34,200
+248% +$194K ﹤0.01% 11727
2021
Q1 		$93K Sell
13,800
-8,100
-37% -$44.9K ﹤0.01% 12526
2020
Q4 		$100K Buy
21,900
+4,300
+24% +$19.1K ﹤0.01% 10224
2020
Q3 		$68K Sell
17,600
-50,900
-74% -$218K ﹤0.01% 9475
2020
Q2 		$326K Buy
68,500
+33,900
+98% +$140K ﹤0.01% 7771
2020
Q1 		$120K Sell
34,600
-4,000
-10% -$16.9K ﹤0.01% 8488
2019
Q4 		$186K Buy
38,600
+3,900
+11% +$13.6K ﹤0.01% 8242
2019
Q3 		$101K Buy
+34,700
New +$121K ﹤0.01% 8476
2019
Q2 		– Sell
-13,000
Closed -$184K – 9114
2019
Q1 		$184K Buy
+13,000
New +$172K ﹤0.01% 8262
2018
Q4 		– Sell
-10,500
Closed -$233K – 9036
2018
Q3 		$233K Buy
+10,500
New +$221K ﹤0.01% 7984

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Citadel Advisors's AMRX Position: Q1 2026 in Review

Citadel Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 91% in Q1 2026, selling an estimated $75.2M and leaving 577,419 shares worth $7.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3770.

Citadel Advisors first reported a position in AMRX in Q2 2018 and has held it in 29 quarters since. The position peaked at $77.8M in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Citadel Advisors held 577,419 shares of Amneal Pharmaceuticals worth $7.18M as of Q1 2026.
  • Citadel Advisors sold 5,598,318 Amneal Pharmaceuticals shares in Q1 2026, an estimated $75.2M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3770 holding.
  • Citadel Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Amneal Pharmaceuticals position peaked at $77.8M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.